Clinical trials: Vascular Pathology
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myocardial Infarction
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
This study will evaluate change in heart muscle function from baseline to three months and twelve months in participants who present with a heart attack and a completely occluded coronary artery.
- Trial name
- NCT01324453
- Testing
- Post Conditioning + Primary PCI, Standard Primary PCI
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Minneapolis Heart Institute Foundation
Stroke, Acute, Stroke
Treatments for Recovery of Hand Function in Acute Stroke Survivors
Impaired hand function is one of the most frequently persisting consequences of stroke. The purpose of this study is to investigate whether two different types of treatment improve recovery of hand function after stroke.
- Conditions
- Stroke, Acute, Stroke, Hemiparesis, Hemiplegia
- Trial name
- NCT00565045
- Testing
- Neuromuscular electrical stimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- MetroHealth Medical Center
Stroke, Brain Ischemia
Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions
Dexmedetomidine is a unique sedative medication able to provide sedation without causing respiratory depression and maintaining neurological functions.
- Conditions
- Stroke, Brain Ischemia, Vasospasm, Intracranial, Hemorrhage, Intracranial
- Trial name
- NCT01845441
- Testing
- Dexmedetomidine, Fentanyl, Midazolam
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University Hospitals Cleveland Medical Center
Atrial Fibrillation, Stroke
Patient Convenience Study (RE-SONANCE)
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02684981
- Where
- 12 sites in Austria, Bulgaria and 10 more
- Volunteers
- 9,472 people
- Sponsor
- Boehringer Ingelheim
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease
Metformin to Reduce Heart Failure After Myocardial Infarction
The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic…
- Conditions
- ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease, Heart Failure, Diabetes
- Trial name
- GIPS-III (NCT01217307)
- Testing
- Metformin
- Where
- Netherlands
- Volunteers
- 380 people
- Sponsor
- University Medical Center Groningen
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Pre-clinical data and recently published clinical data suggest a synergistic effect between lenalidomide and dexamethasone. We hypothesize that a combination of lenalidomide-dexamethasone can overcome rituximab resistance.
- Conditions
- Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT00783367
- Testing
- Lenalidomide, Dexamethasone, Rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ischemic Heart Disease, Angina Pectoris
Absorb GT1 Japan PMS
The purpose of the Surveillance is to know the frequency and status of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect efficacy and safety information for…
- Conditions
- Ischemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Coronary Artery Occlusion
- Trial name
- NCT03409731
- Testing
- ABSORB GT1 BVS
- Where
- 15 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Abbott Medical Devices
Stroke, Hemispatial Neglect
Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance
To find out if spatial neglect following stroke and brain injury can be reduced using guanfacine, a drug that was shown to improve neglect in two stroke patients in a previous pilot study (Malhotra et al, 2006).
- Trial name
- GASNIV (NCT00955253)
- Testing
- Guanfacine
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Imperial College London
Atrial Fibrillation, Deep Vein Thrombosis
Weekly Monitoring Strategy of Capillary INR Versus Monthly Monitoring Strategy of Venous INR in Elderly Patients in a Nursing Home.
This primary care study aims to compare the "time in therapeutic range" (TTR) of two strategies for monitoring the international normalized ratio (INR) over 6 months in nursing homes.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Stroke
- Trial name
- INR-CAP (NCT05561244)
- Testing
- Weekly monitoring using the capillary International Normalised Ratio strategy
- Where
- 33 sites in France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
End Stage Renal Disease, Vascular Access Patency
Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
This study is a randomized, placebo-controlled, single blind clinical trial. Seventy patients with ESRD on chronic HD and a functioning AVF will be recruited.
- Trial name
- NCT02335099
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Virginia
Peripheral Arterial Disease, Intermittent Claudication
High Intensity Interval Training In pATiEnts With Intermittent Claudication
This INITIATE study evaluates the use of high-intensity interval training as a treatment modality for patients with intermittent claudication - an ambulatory leg pain caused by narrowed arteries that supply the lower limbs.
- Trial name
- INITIATE (NCT04042311)
- Testing
- High-intensity interval training
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Angina, Stable, Chest Pain
Acupuncture for Individuals With Stable Angina
This RCT aims to determine if it is possible to perform acupuncture on men and women diagnosed with stable angina who have symptoms, chest pain, and/or chest discomfort.
- Conditions
- Angina, Stable, Chest Pain, Microvascular Angina, Heart Failure
- Trial name
- AIMS-A (NCT02914834)
- Testing
- Acupuncture, Non-pain related video health education
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Illinois Chicago
Trauma, Hemorrhagic Shock
Control of Major Bleeding After Trauma Study
Bleeding is the most avoidable cause of death in trauma patients. Up to one-third of severely injured trauma patients are found to be coagulopathic and forty percent of the mortality following severe injury is due to…
- Trial name
- COMBAT (NCT01838863)
- Testing
- Type AB plasma, Crystalloid fluid (standard of care for resuscitation)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Denver Health and Hospital Authority
Thrombocytopenia, Multiple Myeloma
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
Eltrombopag is a compound that may help stimulate the production of platelets. This drug has been used in treatment of low platelet counts caused by a disorder called idiopathic thrombocytopenic purpura and information from those…
- Trial name
- NCT01484314
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Obstetric Labor Complications, Hemorrhage
Coagulation Factor Changes Associated With Postpartum Hysterectomies
The purpose of this study is to examine components of the coagulation system in women undergoing postpartum hysterectomy and to compare laboratory parameters of coagulation in these women to women at increased risk for a…
- Conditions
- Obstetric Labor Complications, Hemorrhage, Complications; Cesarean Section
- Trial name
- NCT00456547
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Stable Angina
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
- Trial name
- NCT02575833
- Testing
- Erenumab
- Where
- 33 sites in United States, Bulgaria and 8 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Ischemic Stroke
Treatment With Intent to Generate Endovascular Reperfusion
Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset.
- Trial name
- TIGER (NCT03474549)
- Testing
- Tigertriever revascularization device
- Where
- 17 sites in United States, Israel
- Volunteers
- 160 people
- Sponsor
- Rapid Medical